


Amendments to the Claims

This claim listing will replace all prior versions of claims and claim listings in the application:

WE CLAIM:




1. (Previously presented) A compound structurally represented by Formula I







Formula (I)

or pharmaceutically acceptable salts thereof wherein:

R¹ is



R² is





wherein;

R^3 is hydrogen,

-(C₁-C₄) alkyl,

R^4 is

-(C₁-C₄) alkyl,

-(C₁-C₄) alkylene -phenyl,

wherein R^3 and R^4 can cyclize to form, together with the nitrogen to which they are attached, a five or six-membered ring, wherein optionally one of the carbons of the ring formed by said nitrogen, R^3 , and R^4 , is replaced by a nitrogen or oxygen, and wherein said ring is optionally further substituted by R^5 , and


R^5 is hydrogen,

-(C₁-C₄) alkyl, wherein optionally R^5 forms a 3 to five membered ring with the nitrogen containing ring to which it is attached,

-(C₁-C₄) alkylene -N-pyrrolidinyl,





-(C₁-C₄) alkylene -N- piperidinyl;






provided that when R^1 is -CH₂N R^3R^4 or -CONR³ R^4 , then R^2 is








2. (Canceled)
3. (Original) The compound of claim 1, wherein R^1 is CONR³ R^4 , and R^3 and R^4 cyclize to form, together with the nitrogen to which they are attached, a five membered ring, and said ring is further substituted by -CH₂- pyrrolidinyl.
4. (Original) The compound of claim 1, wherein R^1 is CH₂NR³ R^4 , and R^3 and R^4 cyclize to form, together with the nitrogen to which they are attached, a five membered ring, and said ring is further substituted by -CH₂- pyrrolidinyl.
5. (Original) The compound of claim 3 wherein R^2 is N R^3R^4 , and R^3 and R^4 cyclize to form, together with the nitrogen to which they are attached, a five membered ring.

6. (Original) The compound of claim 4 wherein R^2 is $N R^3 R^4$, and R^3 and R^4 cyclize to form, together with the nitrogen to which they are attached, a five membered ring.
7. (Previously presented) The compound of claim 1, further represented by any one of the formula selected from the group consisting of:

Example Number	
1	
2	
3	
4	




5	
6	
8	
9	
13	


14	
15	
16	
17	
18	

or a pharmaceutically acceptable salt thereof.

8. (Previously presented) A pharmaceutical composition which comprises a compound of claim 1 and a pharmaceutically acceptable carrier.
9. (Canceled)
10. (Canceled)
11. (Previously presented) A method for treatment or prevention of obesity which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of Claim 1.

12. (Canceled)
13. (Canceled)
14. (Canceled)
15. (Canceled)
16. (Withdrawn) A compound selected from the group consisting of:

Example Number	
7	
10	
11	



or a pharmaceutically acceptable salt thereof.